Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer

Daniel G. Stover, A. Craig Lockhart, Jordan D. Berlin, Emily Chan, Alan B. Sandler, Jeffery A. Sosman, Victoria Middlebrook, Steven Nicol, MacE L. Rothenberg

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: To identify the maximum tolerated dose (MTD) and describe dose-limiting toxicities (DLT) of pemetrexed and oxaliplatin given on a once-every-2-week schedule in patients with metastatic cancer. Patients and methods: Twenty-five patients were enrolled. Due to toxicities observed at the first dose level in unselected patients, a second MTD was determined in patients who had received zero to two prior chemotherapy regimens. Results: DLT was observed at dose level 1-pemetrexed 400 mg/m2 and oxaliplatin 85 mg/m2-in the form of grade 3 fatigue in two of six patients. Enrollment was then limited to lightly pretreated patients and DLT was observed at dose level 2-pemetrexed 500 mg/m2 and oxaliplatin 85 mg/m 2-in the form of neutropenic fever in one of five patients. Complete response was confirmed in one patient (squamous cell carcinoma of the head and neck) and partial response was confirmed in three patients. Conclusions: The combination of pemetrexed and oxaliplatin can be safely administered at doses of 400 to 500 mg/m2 of pemetrexed and 85 mg/m2 in patients without extensive prior therapy and 300 and 85 mg/m2, respectively, every 2 weeks in patients with more extensive prior therapy. Based on promising results observed in this study, a phase II trial in patients with recurrent head and neck cancer has been initiated.

Original languageEnglish (US)
Pages (from-to)339-345
Number of pages7
JournalInvestigational New Drugs
Issue number4
StatePublished - Aug 2008


  • Clinical trial
  • Oxaliplatin
  • Pemetrexed
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer'. Together they form a unique fingerprint.

Cite this